Polar Asset Management Partners’s Pacific Biosciences PACB Stock Holding History

Polar Asset Management Partners’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-322,800	Closed	-$3.17M	–	855
2023 Q4	$3.17M	Sell	322,800 -510,200	-61%	-$4.17M	0.05%	302
2023 Q3	$6.96M	Buy	833,000 +266,300	+47%	+$3.04M	0.15%	180
2023 Q2	$7.54M	Sell	566,700 -95,000	-14%	-$1.15M	0.14%	194
2023 Q1	$7.66M	Buy	+661,700	New	+$6.58M	0.12%	243
2022 Q2	–	Sell	-476,500	Closed	-$4.34M	–	1396
2022 Q1	$4.34M	Buy	+476,500	New	+$5.49M	0.05%	477
2019 Q3	–	Sell	-475,000	Closed	-$2.87M	–	442
2019 Q2	$2.87M	Buy	475,000 +380,000	+400%	+$2.66M	0.05%	234
2019 Q1	$687K	Buy	+95,000	New	+$687K	0.02%	258

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Polar Asset Management Partners's PACB Position: Q1 2024 in Review

Polar Asset Management Partners sold out of Pacific Biosciences (PACB) in Q1 2024, closing a stake of 322,800 shares — an estimated $3.17M sold.

Polar Asset Management Partners first reported a position in PACB in Q1 2019 and held it in 7 quarters. The position peaked at $7.66M in Q1 2023. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

Polar Asset Management Partners reported no remaining Pacific Biosciences position as of Q1 2024 after selling out during the quarter.
Polar Asset Management Partners sold 322,800 Pacific Biosciences shares in Q1 2024, an estimated $3.17M.
Polar Asset Management Partners first reported a position in Pacific Biosciences in Q1 2019 and held it in 7 quarters.
Polar Asset Management Partners's Pacific Biosciences position peaked at $7.66M in Q1 2023.
268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on Polar Asset Management Partners's 13F filing for Q1 2024, filed 15 May 2024.